Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HCYTD NASDAQ:LGMK OTCMKTS:RSLSD NASDAQ:TTOO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCYTDH-CYTE$2.02-49.5%$2.02$2.02▼$77.00$521K1.12103 shs400 shsLGMKLogicMark$0.01+5.9%$0.00$0.00▼$8.74$2.94M1.4881.77 million shs13.97 million shsRSLSDReShape Lifesciences$0.00$2.91▼$82.80$1.90M2.031,362 shs6,500 shsTTOOT2 Biosystems$0.08+344.4%$0.12$0.00▼$4.90$1.68M0.43559,504 shs23,253 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCYTDH-CYTE0.00%0.00%0.00%0.00%0.00%LGMKLogicMark+5.88%+58.82%+68.75%-69.14%-99.95%RSLSDReShape Lifesciences0.00%0.00%0.00%0.00%0.00%TTOOT2 Biosystems+344.44%+426.32%-41.82%-44.48%-98.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCYTDH-CYTEN/AN/AN/AN/AN/AN/AN/AN/ALGMKLogicMark0.6589 of 5 stars0.03.00.00.02.80.00.6RSLSDReShape LifesciencesN/AN/AN/AN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCYTDH-CYTE 0.00N/AN/AN/ALGMKLogicMark 0.00N/AN/AN/ARSLSDReShape Lifesciences 0.00N/AN/AN/ATTOOT2 Biosystems 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCYTDH-CYTE$1.61M0.32N/AN/A($31.45) per share-0.06LGMKLogicMark$9.88M0.31N/AN/A$148.65 per share0.00RSLSDReShape Lifesciences$610K0.00N/A0.08$341.84 per share0.00TTOOT2 Biosystems$7.68M0.22N/AN/A($6.91) per share-0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCYTDH-CYTE-$4.80MN/A0.00∞N/A-450.40%N/A-777.68%N/ALGMKLogicMark-$14.55M-$223.50N/A∞N/A-141.96%-124.91%-92.05%8/12/2025 (Estimated)RSLSDReShape Lifesciences-$81.15MN/A0.00N/AN/A-668.58%-163.22%-52.10%N/ATTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%10/6/2025 (Estimated)Latest HCYTD, TTOO, RSLSD, and LGMK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025LGMKLogicMark-$0.03N/AN/AN/A$2.35 millionN/A5/15/2025Q1 2025LGMKLogicMark-$0.03-$0.12-$0.09-$0.12$2.23 million$2.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCYTDH-CYTEN/AN/AN/AN/AN/ALGMKLogicMarkN/AN/AN/AN/AN/ARSLSDReShape LifesciencesN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCYTDH-CYTEN/A0.120.12LGMKLogicMarkN/A3.733.29RSLSDReShape Lifesciences0.051.171.07TTOOT2 BiosystemsN/A0.400.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCYTDH-CYTEN/ALGMKLogicMark7.88%RSLSDReShape LifesciencesN/ATTOOT2 Biosystems23.18%Insider OwnershipCompanyInsider OwnershipHCYTDH-CYTE5.24%LGMKLogicMark2.17%RSLSDReShape LifesciencesN/ATTOOT2 Biosystems0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCYTDH-CYTE8258,000244,000Not OptionableLGMKLogicMark20576.31 million2.65 millionNo DataRSLSDReShape Lifesciences50354,000N/ANot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableHCYTD, TTOO, RSLSD, and LGMK HeadlinesRecent News About These CompaniesTTOO T2 Biosystems, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comT2 Biosystems Inc. (TTOO) After Hours QuoteJune 10, 2025 | nasdaq.comDespite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?March 5, 2025 | 360dx.com3T2 Biosystems initiates major layoffs, seeks asset saleFebruary 22, 2025 | uk.investing.comMedical diagnostics firm T2 Biosystems cuts ‘substantially all’ workersFebruary 18, 2025 | bizjournals.comT2 Biosystems to be delisted from NasdaqFebruary 11, 2025 | msn.comT2 Biosystems stock plunges to 52-week low of $0.22January 30, 2025 | msn.comT2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?January 24, 2025 | bovnews.comBT2 Biosystems stock plunges to 52-week low of $0.25January 21, 2025 | msn.comT2 Biosystems amends loan terms, extends maturity dateJanuary 18, 2025 | msn.comT2 Biosystems reports preliminary Q4 revenue $2.3MJanuary 7, 2025 | markets.businessinsider.comT2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024January 7, 2025 | markets.businessinsider.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsJanuary 7, 2025 | finance.yahoo.comT2 Biosystems Enhances Governance and Leadership StabilityJanuary 3, 2025 | tipranks.comT2 Biosystems announces sale of four T2Dx Intruments to European distributorDecember 18, 2024 | markets.businessinsider.comT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorDecember 18, 2024 | finance.yahoo.comT2 Biosystems achieves milestone with 250,000th novel sepsis test shippedDecember 17, 2024 | markets.businessinsider.comT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyDecember 17, 2024 | markets.businessinsider.comT2 Biosystems extends multi-year supplier agreement with VizientDecember 16, 2024 | markets.businessinsider.comT2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection ProductsDecember 16, 2024 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCYTD, TTOO, RSLSD, and LGMK Company DescriptionsH-CYTE OTCMKTS:HCYTD$2.02 -1.98 (-49.50%) As of 07/11/2022H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.LogicMark NASDAQ:LGMK$0.0054 +0.00 (+5.88%) As of 08/1/2025 03:59 PM EasternLogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company's devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one's health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.ReShape Lifesciences OTCMKTS:RSLSDReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.T2 Biosystems NASDAQ:TTOO$0.08 +0.06 (+344.44%) As of 08/1/2025 01:08 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
